Figure 3
hVEGF siRNA/SilenceMag and 131 I-hVEGF siRNA/SilenceMag administration guided by an EMF inhibited HCC tumor growth in nude mice. A: tumor growth curve after. hVEGF siRNA/SilenceMag and 131I-hVEGF siRNA/SilenceMag xenograft. (1) 131I-hVEGF siRNA/SilenceMag with EMF; (2) 131I-hVEGF siRNA/SilenceMag without EMF; (3) hVEGF siRNA/SilenceMag with EMF; (4) control group with saline solution. B: VEGF protein expression by immunohistochemical assay in nude mice bearing HepG2 xenografts 28 days post siRNA administration (magnification × 200). VEGF protein shows as brownish staining. (a) 131I-hVEGF siRNA/SilenceMag administered intravenously guided by EMF; (b) 131I-hVEGF siRNA/SilenceMag administered intravenously in the absence of EMF; (c) hVEGF siRNA/SilenceMag administered intravenously guided by EMF; (d) the control group. C: The weight log of the nude mice bearing the HepG2 HCC xenograft from day 0, injection of hVEGF siRNA/SilenceMag, to day 28. (1) 131I-hVEGF siRNA/SilenceMag with EMF; (2) 131I-hVEGF siRNA/SilenceMag without EMF; (3) hVEGF siRNA/SilenceMag with EMF; (4) control group.